DLD Asset Management LP Buys New Position in Design Therapeutics, Inc. $DSGN

DLD Asset Management LP purchased a new position in Design Therapeutics, Inc. (NASDAQ:DSGN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $376,000. DLD Asset Management LP owned 0.09% of Design Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of DSGN. Woodline Partners LP bought a new stake in shares of Design Therapeutics during the 1st quarter valued at $2,492,000. Jane Street Group LLC bought a new position in shares of Design Therapeutics in the first quarter worth approximately $70,000. Strs Ohio purchased a new stake in shares of Design Therapeutics in the first quarter worth $87,000. Los Angeles Capital Management LLC purchased a new stake in shares of Design Therapeutics in the second quarter worth $43,000. Finally, Geode Capital Management LLC raised its position in shares of Design Therapeutics by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 794,008 shares of the company’s stock valued at $2,676,000 after purchasing an additional 18,511 shares during the period. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Craig Hallum started coverage on Design Therapeutics in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 price target for the company. Leerink Partners set a $14.00 price objective on Design Therapeutics and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Oppenheimer initiated coverage on Design Therapeutics in a research report on Wednesday, January 7th. They set an “outperform” rating and a $18.00 target price for the company. Royal Bank Of Canada raised Design Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $6.00 to $13.00 in a report on Thursday, November 20th. Finally, Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Design Therapeutics Stock Down 0.4%

Shares of DSGN stock opened at $10.05 on Monday. The company’s fifty day simple moving average is $9.96 and its two-hundred day simple moving average is $8.19. Design Therapeutics, Inc. has a 52 week low of $2.60 and a 52 week high of $11.14. The stock has a market cap of $572.49 million, a P/E ratio of -8.45 and a beta of 1.63.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.